Review Article
Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients
| Fábryová 脙鈥灻偮絬bomíra* | |
| Department for diabetes and metabolic disorders, Bratislava, Slovak Republic | |
| Corresponding Author : | Fábryová 脙鈥灻偮絬bomíra Department for diabetes and metabolic disorders Bratislava, Slovak Republic Tel: 421252620738 E-mail: lfabryova@metabolklinik.sk |
| Received: September 24, 2015; Accepted: October 07, 2015; Published: October 20, 2015 | |
| Citation: Lubomíra F (2015) Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients. J Obes Weight Loss Ther 5:277. doi:10.4172/2165-7904.1000277 | |
| Copyright: © 2015 脙鈥灻偮絬bomíra F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
| Related article at , | |
Abstract
The first line in the treatment of obesity is a combination of a low calorie diet, increased physical activity and behavioural therapy. Unless these options fail, should be considered an effective and safe pharmacotherapy. The market situation in anti-obesity treatment will change in a relatively short time; the combination anti-obesity therapy is entering into clinical practice. Currently in Europe we have three drugs approved for long-term chronic treatment of obesity. In addition to the orlistat EMA approved a combination of naltrexon SR/bupropion SR and liraglutide 3.0 mg. A specific feature management of obese diabetic patients is the selection of weight neutral or weight-reducing anti-diabetic treatment (oral anti-diabetics, insulin), but also weight neutral treatment associated with co-morbidities.
